



Australian Precision

Oncology Symposium


2024



Omico




Cancer
meets its match




Precision Oncology Advances and Future Sustainability

We warmly invite you to exclusively attend the Australian Precision Oncology Symposium 2024!

This year, we are focusing on 'Precision Oncology Advances and Future Sustainability', a theme that mirrors our concerted efforts to accelerate breakthroughs in targeted cancer treatments and our commitment to future-proof these technologies and methodologies.



Date: Friday 8 - Saturday 9 March 2024



Mode: Face to Face & Online



Location:
Venue - John Niland Scientia Building, UNSW Kensington campus Kensington, NSW, 2052
Address - G19 Library Road, Kensington

Key Dates

Registrations Close - Friday, 1 March 2024

The 1½ day interactive Symposium is designed for an audience of up to 150 delegates including world-renowned medical and academic oncologists, pathologists, clinical researchers and professionals from the pharmaceutical and research sectors.

The Symposium will feature a blend of plenary style lectures and panel discussions that delve into precision oncology topics. These sessions will explore the latest evidence and its implications for health, health systems, and integration into models of care. Additionally, key areas of focus will include the role of real-world data, funding models, as well as discussions on heritability and early detection of cancer in high-risk populations.

The venue can accommodate up to 150 delegates in person and all sessions will also be available for live, online attendance.

For those attending in person, this Symposium offers a unique networking opportunity, fostering collaboration and interaction among participants. Attendees will have the chance to connect with experts in the field, share insights, and build valuable professional relationships, enhancing the overall experience and impact of the event.

For virtual participants, you have the flexibility to access any or all of the five sessions in the program, tailoring your experience to focus on the topics most pertinent to your specific areas of interest.

We look forward to welcoming you to the Australian Precision Oncology Symposium 2024 (APOS 24) educational event. Further details on key aspects of the event are provided in the subsequent pages.

International Speakers.

Christoph Benedikt Westphalen, Germany

Head, Comprehensive Cancer Centre Munich
Department of Medicine III
University Hospital, Munich



Benedikt Westphalen is widely recognized in the field of precision oncology and is an active member of organisations like ESMO, Deutsche Krebsgesellschaft, and the German Cancer Aid.

Since 2017, he has led the precision oncology program at the Comprehensive Cancer Centre in Munich, which he currently represents within the European Reference Network for rare cancers (EURACAN). In 2022, Dr. Westphalen was elected to join the EU Commission Mission expert group: Mission Board for Cancer. Since January 2024, Dr. Westphalen chairs ESMO's Translational Research and Precision Medicine Working Group.

He serves as principal investigator and co-investigator on numerous clinical trials and has also received several prestigious awards in recognition of his work, which currently focuses on clinical and translational research, particularly in pancreatic cancer and rare cancers.

Sahar van Waalwijk van Doorn-Khosrovani, The Netherlands

PharmD, PhD, Pharmacist Medicine & Society
CZ Health Insurance



Sahar van Waalwijk van Doorn-Khosrovani (PharmD-PhD), a pharmacist at Dutch health insurance CZ, brings a unique perspective to this Symposium leveraging her expertise at the intersection of pharmacy, healthcare policy, and cutting-edge research. As a key member of the National Payer's Evaluation Committee for Specialized Medicines and Companion Diagnostics, she directly influences reimbursement decisions in the Netherlands.

Affiliated with Leiden University Medical Centre's Oncology Department, Sahar is part of the National Horizon Scanning group for oncology and hematology. Leading a work package for Prime-Rose, an EU Cancer Mission-funded precision cancer medicine trial network, she integrates policy and practice. Her multifaceted role encompasses advisory positions for research funds, underscoring her commitment to advancing precision oncology.

Professor Cristin Print, New Zealand

Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland




Cristin Print works at the interface between research and clinical use of genomics and bioinformatics. Graduating in Medicine from the University of Auckland in 1989, he embarked on a research journey during his tenure as a house surgeon in Dunedin, NZ. His molecular immunology PhD paved the way for impactful postdoctoral stints at the Walter and Eliza Hall Institute in Melbourne, Australia, and Cambridge University, UK.

In 2005 he returned to the University of Auckland where he leads a cross-disciplinary research team of clinicians and scientists who use genomics and bioinformatics to better understand cancer. Currently leading the Genomics Into Medicine Strategic Research Initiative, he chairs the Auckland Regional Biobank Scientific Advisory Board and is Principal Investigator in NZ's Rakeiora program, the Maurice Wilkins Centre for Biodiscovery, and the NZ Healthier Lives National Science Challenge. Cris brings to the Symposium his broad experience of research and clinical applications of genomics and bioinformatics, and will lead a future-focused exploration of precision oncology research and practice.


Program Overview.

In addition to three international speakers, APOS 24 will feature a number of Australian experts contributing to the educational program. A preliminary outline of the program is shown below, noting that this is subject to change. All sessions will be held at the John Niland Scientia Building G19, Library Road, UNSW, Kensington Campus.

Friday, 8 March 2024.



Saturday, 9 March 2024.




Sessions Overview.

Session 1 – Friday, 8 March 2024

Session 1: Health Impact – Chaired by David Thomas

This session will explore the current and future implementation of precision oncology in Germany with insight from our guest speaker Benedikt Westphalen, and data shared from key research programs.




Clinical impact: precision oncology in Germany, Australia's MoST program and cancers of unmet need.

1:00 – 1:10pm	Welcome and opening remarks Acknowledgment to the traditional custodians of the land
1:10 – 1:45pm	Future of precision oncology in Germany Benedikt Westphalen – 25min talk, 10min Q&A
1:45 – 2:05pm	MoST paper Frank Lin – 15min talk, 5min Q&A
2:05 – 2:25pm	Implementing precision oncology in the hospital system Natalie Taylor – 15min talk, 5min Q&A
2:25 – 2:45pm	ASPIRATION Nick Pavlakis – 15min talk, 5min Q&A

Session 2 – Friday, 8 March 2024

Session 2: Health Systems – Chaired by Natalie Taylor

We will consider the future of precision oncology in New Zealand, led by our guest speaker Cristin Print. Implementation of precision oncology within hospital systems and the future of molecular profiling will also be covered.



Precision oncology in public health: the New Zealand perspective, health technology assessment, implementation science and the future of molecular profiling.

3:15 – 3:50pm	Future of precision oncology in New Zealand Cristin Print – 25min talk, 10min Q&A
3:50 – 4:10pm	PrOSPeCT – public: private partnership David Thomas – 15min talk, 5min Q&A
4:10 – 4:30pm	HTA in the era of precision oncology Bonny Parkinson – 15min talk, 5min Q&A
4:30 – 4:50pm	The future of molecular profiling: proteomics Roger Reddel – 15min talk, 5min Q&A
4:50 – 5:20pm	Panel: precision oncology in 2030 – Chaired by David Thomas Benedikt Westphalen, Cristin Print, Sahar Van Waalwijk Doorn-Khosrovani, Nick Pavlakis – 30 min talk & Q&A

Session 3 – Saturday, 9 March 2024

Session 3: Real World Data – Chaired by Ronald Chan

Our guest speaker, Sahar Van Waalwijk van Doorn-Khosrovani, will consider the funding of precision oncology based on her experience in Europe. Discussions will follow on the application and utilisation of real-world data and partnerships.



Data-driven healthcare innovation: creative funding models in The Netherlands, data use and commercialisation, essential partnerships.

9:00 – 9:05am	Opening remarks
9:05 – 9:40am	Funding precision oncology Sahar Van Waalwijk Doorn-Khosrovani – 25min talk, 10min Q&A
9:40 – 10:00am	Commercialising real world data in precision oncology Neil Soderlund – 15min talk, 5min Q&A
10:00 – 10:20am	CUPISCO and beyond Linda Mileshkin – 15min talk, 5min Q&A

Session 4 – Saturday, 9 March 2024

Session 4: Heritability and Early Detection – Chaired by Mandy Ballinger

Covering preventive DNA testing, early detection, and germline findings from ongoing programs.



Personalised risk management in cancer: from individuals to the population.

11:00 – 11:30am	The DNA screen program Paul Lacaze – 25min talk, 10min Q&A
11:30 – 11:50am	Integrating potential germline findings from tumour profiling into patient care Milita Zaheed – 15min talk, 5min Q&A
11:50 – 12:10pm	SMOC: early detection Mandy Ballinger – 15min talk, 5min Q&A
12:10 – 12:30pm	Germline findings in Zero Noemi Fuentes Bolanos – 15min talk, 5min Q&A

Live Molecular Oncology Board – Saturday, 9 March 2024

Chaired by David Thomas

1:15 – 2:30pm	Individual cases from molecular pathology to treatment recommendations Frank Lin, Milita Zaheed, John Grady, David Thomas, Min Li Huang
2:30pm	Close David Thomas



Contact.

Should you have any questions or require further information, please contact:

Fidan Rasimoglou - Marketing Manager
Omico
Hilmer Building (E10), Union Rd, UNSW
Kensington, NSW, 2052
Email: f.rasimoglou@omico.org.au

Omico.com.au

Follow us:



©Copyright 2023. Australian Genomic Cancer Medicine Centre Ltd, trading as Omico, is a not for profit company limited by guarantee. Hilmer building (E10), Union Rd, UNSW, Kensington, NSW, 2052.